World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
70291
World Ranking
3985
National Ranking
19

Walter Reinisch publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Walter Reinisch sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 889 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Walter Reinisch D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Walter Reinisch sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 118 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Walter Reinisch is affiliated with the Medical University of Vienna in Austria. Their research focuses primarily on areas within medicine and biochemistry, genetics, and molecular biology. Their work includes substantial contributions to subfields such as genetics, epidemiology, surgery, immunology, and oncology.

The scientist's main areas of study encompass inflammatory bowel disease, microscopic colitis, eosinophilic esophagitis, autoimmune and inflammatory disorders, biosimilars and bioanalytical methods, immunodeficiency and autoimmune disorders, and Helicobacter pylori-related gastroenterology studies.

Walter Reinisch has published extensively in several key journals, with frequent contributions in:

  • Journal of Crohn's and Colitis
  • Gastroenterology
  • The American Journal of Gastroenterology
  • Inflammatory Bowel Diseases
  • Clinical Gastroenterology and Hepatology

Among their recent papers are:

  • STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD, 2021, Gastroenterology
  • Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry, 2020, Gastroenterology
  • Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials, 2022, The Lancet
  • Effect of IBD medications on COVID-19 outcomes: results from an international registry, 2020, Gut
  • Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease, 2021, Gastroenterology

Walter Reinisch frequently collaborates with several coauthors, including:

  • Neeraj Narula
  • Emily C L Wong
  • John K. Marshall
  • Parambir S. Dulai
  • Geert D'Haens

Best Publications

  • Infliximab for induction and maintenance therapy for ulcerative colitis.

    Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch

  • Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

    Jean Frédéric Colombel;William J. Sandborn;Walter Reinisch;Gerassimos J. Mantzaris

  • Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

    L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

  • STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

    Dan Turner;Amanda Ricciuto;Ayanna Lewis;Ferdinando D’Amico

  • Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

    Paul Moayyedi;Michael G. Surette;Peter T. Kim;Peter T. Kim;Josie Libertucci

  • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

    Wolfgang Hueber;Bruce E Sands;Steve Lewitzky;Marc Vandemeulebroecke

  • Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

    William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens

  • Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

    Axel Dignass;James O. Lindsay;Andreas Sturm;Alastair Windsor

  • Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    William J. Sandborn;Gert van Assche;Walter Reinisch;Jean–Frederic Colombel

  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

    Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude

  • European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

    Jean-François Rahier;F Magro;C Abreu;A Armuzzi

  • Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1: Definitions and Diagnosis

    Axel Dignass;Rami Eliakim;Fernando Magro;Christian Maaser

  • Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

    Jean Frédéric Colombel;Paul Rutgeerts;Walter Reinisch;Dirk Esser

  • Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

    Julián Panés;Damián García-Olmo;Gert Van Assche;Jean Frederic Colombel

  • Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

    William J Sandborn;Brian G Feagan;Colleen W Marano;Hongyan Zhang

  • Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    Jean Frederic Colombel;Remo Panaccione;Peter Bossuyt;Milan Lukas

  • Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.

    Erica J. Brenner;Ryan C. Ungaro;Richard B. Gearry;Gilaad G. Kaplan

  • Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

    William J Sandborn;Brian G Feagan;Colleen W Marano;Hongyan Zhang

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

    J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker

Frequent Co-Authors

William J. Sandborn
William J. Sandborn University of California, San Diego
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
Brian G. Feagan
Brian G. Feagan University of Western Ontario
Remo Panaccione
Remo Panaccione University of Calgary
Silvio Danese
Silvio Danese Vita-Salute San Raffaele University
Stefan Schreiber
Stefan Schreiber Kiel University
Geert R. D'Haens
Geert R. D'Haens University of Amsterdam
Julián Panés
Julián Panés University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying Medicine in the USA but want alternative options or entry points into healthcare, various online degrees can help you start your journey. Nursing is a popular pathway, and there are easiest rn program to get into options for those seeking less competitive admissions. Some programs also offer a unique advantage by being a nursing school without teas test or HESI requirements, making the process more accessible for aspiring nurses.

Another in-demand field is medical billing and coding. You can find medical billing and coding schools that accept fafsa, which can help lower the cost and provide vital skills for a growing sector. For those with management goals, pursuing the best online healthcare administration degree offers accelerated learning and flexible career opportunities.

Exploring these alternatives not only diversifies your career options but also makes it easier to enter the healthcare field—no matter your background or experience.

Best Scientists Citing Walter Reinisch

Trending Scientists